Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive

Edesa Biotech, Inc.

Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).
Operating expenses fell to $2.06M from $5.80M in Q3; R&D down $3.52M to $1.03M due to lower clinical and manufacturing costs.
Cash $6.46M, working capital $5.39M at June 30, 2023; raised $4.63M YTD from share/warrant sales.
Positive university study data for paridiprubart (EB05) against respiratory pathogens; Phase 3 ARDS study ongoing.
Completed Phase 2b dermatitis study with favorable topline; planning vitiligo Phase 2 and systemic sclerosis Phase 2 studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.